Luiz Fernando Venegas, MD

Articles by Luiz Fernando Venegas, MD

A Phase II Study of Doxorubicin/Paclitaxel Plus G-CSF for Metastatic Breast Cancer

ByGilberto Schwartsmann, MD, PhD,Denis Ricardo Mans, PhD,Carlos Henrique Menke, MD,Nilton Xavier, MD,Maira Caleffi, MD, PhD,Ferreira Filho, MD, PhD,Hugo Schunemann, MD,Luciane Kalakun, RN,Richard Koya, MD,Paula Pohlman, MD,Luiz Fernando Venegas, MD

April 1st 1997

This phase II trial was conducted to evaluate the percentage of objective responses and the toxicity profile of combination doxorubicin (Adriamycin) and paclitaxel (Taxol) with granulocyte colony-stimulating factor as first-line

Latest Updated Articles

A Phase II Study of Doxorubicin/Paclitaxel Plus G-CSF for Metastatic Breast Cancer
Published: April 1st 1997 | Updated:

Luiz Fernando Venegas, MD

Articles by Luiz Fernando Venegas, MD

A Phase II Study of Doxorubicin/Paclitaxel Plus G-CSF for Metastatic Breast Cancer

Latest Updated Articles

Trending on CancerNetwork

AI-Powered Scout Platform Could Enhance Oncology Decision-Making With Data- and Expert-Driven Insights

FDA Grants Interchangeability Designation to 2 Denosumab Biosimilars

Sac-TMT Combo Produces Encouraging Activity in Pretreated Metastatic CRPC

Molecular Insights Into Cancer Cachexia: An Evolution in Identifying the Syndrome

Novel SSTR-Targeted Alpha Therapy Shows “Encouraging” Activity in GEP-NETs